![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Synthon B.v. Nijmegen Nl, based in Netherlands, is a pharmaceutical company that stands out with its certifications from FDA.
One of their significant offerings is Everolimus, BHT 2.0%, supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 2021-260 - Rev 01
This Chemical Type CEP, issued on February 23, 2024, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2918 associated with this CEP further emphasizes